Last reviewed · How we verify
99mTc-3PRGD2 injection
At a glance
| Generic name | 99mTc-3PRGD2 injection |
|---|---|
| Also known as | Technetium-99m [99mTc] labeled hydrazinonicotinamide-PEG4-E[PEG4-c(RGDfk)]2, 99mTc-HYNIC-3PRGD2 |
| Sponsor | RDO Pharm. |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- 99mTc-3PRGD2 SPECT/CT for Integrin Imaging of Lung Cancer (PHASE3)
- 99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients (EARLY_PHASE1)
- 99m Tc-3PRGD2 SPECT/CT Imaging in the Diagnosis of Lymph Node Metastasis of Esophageal Carcinoma (NA)
- 99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients (NA)
- 99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients (EARLY_PHASE1)
- A Study of 99mTc-3PRGD2 Injection in Healthy Volunteers (PHASE1)
- 99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 99mTc-3PRGD2 injection CI brief — competitive landscape report
- 99mTc-3PRGD2 injection updates RSS · CI watch RSS
- RDO Pharm. portfolio CI